Determinants of Versican-V1 Proteoglycan Processing by the Metalloproteinase ADAMTS5

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2014 Aug 15

PMID 25122765

Citations 32

Authors

Simon J Foulcer

Courtney M Nelson

Maritza V Quintero

Balagurunathan Kuberan

Jonathan Larkin

Maria T Dours-Zimmermann

Dieter R Zimmermann

Suneel S Apte

Affiliations

Soon will be listed here.

Abstract

Proteolysis of the Glu(441)-Ala(442) bond in the glycosaminoglycan (GAG) β domain of the versican-V1 variant by a disintegrin-like and metalloproteinase domain with thrombospondin type 1 motif (ADAMTS) proteases is required for proper embryo morphogenesis. However, the processing mechanism and the possibility of additional ADAMTS-cleaved processing sites are unknown. We demonstrate here that if Glu(441) is mutated, ADAMTS5 cleaves inefficiently at a proximate upstream site but normally does not cleave elsewhere within the GAGβ domain. Chondroitin sulfate (CS) modification of versican is a prerequisite for cleavage at the Glu(441)-Ala(442) site, as demonstrated by reduced processing of CS-deficient or chondroitinase ABC-treated versican-V1. Site-directed mutagenesis identified the N-terminal CS attachment sites Ser(507) and Ser(525) as essential for processing of the Glu(441)-Ala(442) bond by ADAMTS5. A construct including only these two GAG chains, but not downstream GAG attachment sites, was cleaved efficiently. Therefore, CS chain attachment to Ser(507) and Ser(525) is necessary and sufficient for versican proteolysis by ADAMTS5. Mutagenesis of Glu(441) and an antibody to a peptide spanning Thr(432)-Gly(445) (i.e. containing the scissile bond) reduced versican-V1 processing. ADAMTS5 lacking the C-terminal ancillary domain did not cleave versican, and an ADAMTS5 ancillary domain construct bound versican-V1 via the CS chains. We conclude that docking of ADAMTS5 with two N-terminal GAG chains of versican-V1 via its ancillary domain is required for versican processing at Glu(441)-Ala(442). V1 proteolysis by ADAMTS1 demonstrated a similar requirement for the N-terminal GAG chains and Glu(441). Therefore, versican cleavage can be inhibited substantially by mutation of Glu(441), Ser(507), and Ser(525) or by an antibody to the region of the scissile bond.

Citing Articles

A plastic aggrecan barrier modulated by peripheral energy state gates metabolic signal access to arcuate neurons.

Kuczynski-Noyau L, Karmann S, Alberton P, Martinez-Corral I, Nampoothiri S, Sauve F Nat Commun. 2024; 15(1):6701.

PMID: 39112471 PMC: 11306556. DOI: 10.1038/s41467-024-50798-9.

Combined genetic-pharmacologic inactivation of tightly linked ADAMTS proteases in temporally specific windows uncovers distinct roles for versican proteolysis and glypican-6 in cardiac development.

Mead T, Bhutada S, Foulcer S, Peruzzi N, Nelson C, Seifert D Matrix Biol. 2024; 131:1-16.

PMID: 38750698 PMC: 11526477. DOI: 10.1016/j.matbio.2024.05.003.

Expression and prognosis of ADAMTS18 in different tumors.

Guo W, Zhang Y Front Oncol. 2024; 14:1347633.

PMID: 38482210 PMC: 10933061. DOI: 10.3389/fonc.2024.1347633.

Determination of Versikine Levels by Enzyme-Linked Immunosorbent Assay (ELISA).

Minns A, Santamaria S Methods Mol Biol. 2023; 2747:83-93.

PMID: 38038934 DOI: 10.1007/978-1-0716-3589-6_8.

Phylogenetic inference of the emergence of sequence modules and protein-protein interactions in the ADAMTS-TSL family.

Dennler O, Coste F, Blanquart S, Belleannee C, Theret N PLoS Comput Biol. 2023; 19(8):e1011404.

PMID: 37651409 PMC: 10499240. DOI: 10.1371/journal.pcbi.1011404.

References

Matsumoto K, Kamiya N, Suwan K, Atsumi F, Shimizu K, Shinomura T . Identification and characterization of versican/PG-M aggregates in cartilage. J Biol Chem. 2006; 281(26):18257-63. DOI: 10.1074/jbc.M510330200. View

Bode-Lesniewska B, Dours-Zimmermann M, Odermatt B, Briner J, Heitz P, Zimmermann D . Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem. 1996; 44(4):303-12. DOI: 10.1177/44.4.8601689. View

Landolt R, Vaughan L, Winterhalter K, Zimmermann D . Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development. 1995; 121(8):2303-12. DOI: 10.1242/dev.121.8.2303. View

Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T . Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A. 2009; 106(46):19274-9. PMC: 2780749. DOI: 10.1073/pnas.0909755106. View

Stankunas K, Hang C, Tsun Z, Chen H, Lee N, Wu J . Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev Cell. 2008; 14(2):298-311. PMC: 2274005. DOI: 10.1016/j.devcel.2007.11.018. View

Viapiano M, Hockfield S, Matthews R . BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol. 2008; 88(3):261-72. PMC: 3896091. DOI: 10.1007/s11060-008-9575-8. View

Brown H, Dunning K, Robker R, Pritchard M, Russell D . Requirement for ADAMTS-1 in extracellular matrix remodeling during ovarian folliculogenesis and lymphangiogenesis. Dev Biol. 2006; 300(2):699-709. DOI: 10.1016/j.ydbio.2006.10.012. View

Zimmermann D, Ruoslahti E . Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 1989; 8(10):2975-81. PMC: 401368. DOI: 10.1002/j.1460-2075.1989.tb08447.x. View

Victor X, Nguyen T, Ethirajan M, Tran V, Nguyen K, Kuberan B . Investigating the elusive mechanism of glycosaminoglycan biosynthesis. J Biol Chem. 2009; 284(38):25842-53. PMC: 2757986. DOI: 10.1074/jbc.M109.043208. View

10.

Longpre J, Leduc R . Identification of prodomain determinants involved in ADAMTS-1 biosynthesis. J Biol Chem. 2004; 279(32):33237-45. DOI: 10.1074/jbc.M313151200. View

11.

Kern C, Wessels A, McGarity J, Dixon L, Alston E, Argraves W . Reduced versican cleavage due to Adamts9 haploinsufficiency is associated with cardiac and aortic anomalies. Matrix Biol. 2010; 29(4):304-16. PMC: 2862783. DOI: 10.1016/j.matbio.2010.01.005. View

12.

Rodriguez-Manzaneque J, Westling J, Thai S, Luque A, Knauper V, Murphy G . ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun. 2002; 293(1):501-8. DOI: 10.1016/S0006-291X(02)00254-1. View

13.

Yang B, Yang B, Erwin M, Ang L, Finkelstein J, Yee A . Versican G3 domain enhances cellular adhesion and proliferation of bovine intervertebral disc cells cultured in vitro. Life Sci. 2003; 73(26):3399-413. DOI: 10.1016/j.lfs.2003.06.018. View

14.

Dancevic C, Fraser F, Smith A, Stupka N, Ward A, McCulloch D . Biosynthesis and expression of a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats-15: a novel versican-cleaving proteoglycanase. J Biol Chem. 2013; 288(52):37267-76. PMC: 3873579. DOI: 10.1074/jbc.M112.418624. View

15.

Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D . Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem. 1999; 274(29):20444-9. DOI: 10.1074/jbc.274.29.20444. View

16.

Yee A, Akens M, Yang B, Finkelstein J, Zheng P, Deng Z . The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007; 9(4):R47. PMC: 2206723. DOI: 10.1186/bcr1751. View

17.

Nandadasa S, Foulcer S, Apte S . The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis. Matrix Biol. 2014; 35:34-41. PMC: 5525047. DOI: 10.1016/j.matbio.2014.01.005. View

18.

Williams Jr D, Presar A, Todd Richmond A, Mjaatvedt C, Hoffman S, Capehart A . Limb chondrogenesis is compromised in the versican deficient hdf mouse. Biochem Biophys Res Commun. 2005; 334(3):960-6. DOI: 10.1016/j.bbrc.2005.06.189. View

19.

Fushimi K, Troeberg L, Nakamura H, Lim N, Nagase H . Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem. 2007; 283(11):6706-16. DOI: 10.1074/jbc.M708647200. View

20.

Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S . Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer. 2009; 126(3):640-50. DOI: 10.1002/ijc.24812. View